gene
-
Global generic drug markets will grow to US$221 billion by 2016
Driven by the need to control costs, the use of generic drugs has grown considerably in recent years, even in markets where traditionally they have not been favored.
gene | 23 May 2012
-
US Supreme Court clears way for generic patent challenges
After the ruling, generic manufacturers will now be able to challenge the content of patent descriptions and, if successful, ultimately force approval of the ANDA. Writing for the Court in a unanimous decision, Justice Elena Kagan chastised the FDA for using ambiguous or opaque guidelines and forms that lend to the confusion surrounding patent decisions.
gene | 18 May 2012
-
Agilent launches next-generation pharmaceutical compliance service
The updated software enables delivery of even more reliable, secure and cost-efficient analytical instrument qualification services to the pharmaceutical industry.
gene | 20 March 2012
-
Life Technologies partners with DaAn Gene
Life Technologies announced that it has signed an agreement with DaAn Gene, a Chinese company in molecular in-vitro diagnostics (IVD), to form Life Technologies DaAn Diagnostics, a joint venture diagnostics business in China. The move is expected to contribute to the early diagnosis of oncology, infectious diseases and genetic diseases. Financial terms of the deal were not disclosed.
gene | 05 March 2012
-
Generic drug manufacturers forge alliances in face of tough economic climate
The generic drugs sector’s role as the provider of affordable drugs has widely benefitted public and private health payers keen to control costs. But in the current economic climate, downward pressure on prices is impacting the generic sector, with increases in acquisition and strategic partnering now firmly part of the competitive landscape.
gene | 28 February 2012
-
Genetic Technologies receives CLIA certificate of compliance from Centers for Medicare and MedicAid Services, USA
Genetic Technologies announced that it has received the Certificate of Compliance for its Australian laboratory under the US Clinical Laboratories Improvements Amendments (CLIA) regulations as administered by the Centers for Medicare and Medicaid Services (CMS).
gene | 21 February 2012
-
Phase III studies with VEGF Trap-Eye in wet age-related macular degeneration show sustained improvement in visual acuity
Bayer HealthCare and Regeneron Pharmaceuticals announced that in an integrated analysis of two parallel Phase III studies (VIEW 1 and VIEW 2) in patients with the neovascular form of age-related macular degeneration (wet AMD), patients treated with VEGF Trap-Eye showed a sustained improvement in visual acuity at 96 weeks versus baseline.
gene | 25 January 2012
-
ICON Development Solutions appoints general manager of Asia Pacific
ICON announced that its development solutions division has appointed Dr Daniel Tang as general manager, Asia Pacific. Dr Tang will lead the development of ICON’s early phase activities across the region, including bioanalytical laboratory services, and the development of strong links with key opinion leaders for early phase clinical testing.
gene | 12 December 2011
-
Agilent Technologies signs agreement to supply target enrichment system to Ambry Genetics
Agilent Technologies and Ambry Genetics announced an agreement under which Ambry Genetics will use the Agilent SureSelect Target Enrichment System for exome sequencing services.
gene | 31 October 2011
-
Bio-Images and Medimetrics partner to deliver the next generation of smart pill technology
IntelliCap set to speed up clinical research as part of innovative drug delivery package.
gene | 25 October 2011
